Assignee
SILVER CREEK PHARMACEUTICALS INC
US·10 granted patents·8 pending applications·36 citations·filing 2016–2025
Top patents by PatentIndex Score
18 records- 0194US10988547B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·6 cites·7 claims
- 0293US10858450B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·6 cites·7 claims
- 0393US10407512B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·9 cites·8 claims
- 0490US11814443B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·1 cites·20 claims
- 0590US11155593B2Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5SILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Oct 26, 2021·3 cites·12 claims
- 0689US2024101713A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0788US11673970B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Jun 13, 2023·1 cites·7 claims
- 0887US2023322951A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0986US10040840B2Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissueSILVER CREEK PHARMACEUTICALS INC·Filed 2016·Granted Aug 7, 2018·6 cites·20 claims
- 1086US2025145682A1Compositions and methods of treating tissue damageSILVER CREEK PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1184US10633425B2Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5SILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Apr 28, 2020·4 cites·6 claims
- 1278US12122819B2Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variantSILVER CREEK PHARMACEUTICALS INC·Filed 2022·Granted Oct 22, 2024·0 cites·14 claims
- 1376US11879002B2Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereofSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Jan 23, 2024·0 cites·19 claims
- 1471US2026041738A1Chimeric Proteins and Methods of Use for Treatment of Central Nervous System DisordersSILVER CREEK PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1565US2024245756A1Chimeric proteins and methods of use for treatment of neurodegenerative disordersSILVER CREEK PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1663US2022031812A1Chimeric Proteins and Methods of Use for Treatment of Central Nervous System DisordersSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1760US2024279359A1Chimeric proteins for targeted delivery of growth factors to the glomerulusSILVER CREEK PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1860US2025144175A1Chimeric proteins for treatment of acute radiation syndromeSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SILVER CREEK PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →